PE20240491A1 - Peptidos y metodos para el tratamiento de esclerosis multiple - Google Patents
Peptidos y metodos para el tratamiento de esclerosis multipleInfo
- Publication number
- PE20240491A1 PE20240491A1 PE2022002564A PE2022002564A PE20240491A1 PE 20240491 A1 PE20240491 A1 PE 20240491A1 PE 2022002564 A PE2022002564 A PE 2022002564A PE 2022002564 A PE2022002564 A PE 2022002564A PE 20240491 A1 PE20240491 A1 PE 20240491A1
- Authority
- PE
- Peru
- Prior art keywords
- sequence
- seq
- amino acid
- treatment
- epitope
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 6
- 235000001014 amino acid Nutrition 0.000 abstract 5
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 abstract 3
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 3
- 102000004316 Oxidoreductases Human genes 0.000 abstract 2
- 108090000854 Oxidoreductases Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010012305 Demyelination Diseases 0.000 abstract 1
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 230000001461 cytolytic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000000581 natural killer T-cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Abstract
La presente invencion se refiere a un peptido inmunogenico aislado con una longitud de entre 12 y 50 aminoacidos, comprendiendo dicho peptido inmunogenico: a1) un motivo de oxidorreductasa con la secuencia Zm-[CST]-Xn-C- o Zm-C-Xn-[CST], en donde n es un entero seleccionado de: 2, 0, 1 o 3; m es un entero seleccionado de 2, 1, 0 o 3; X es cualquier aminoacido; Z es cualquier aminoacido; X es cualquier aminoacido; C significa cisteina, S significa serina, T significa treonina; a2) un epitope de celulas T con una secuencia de aminoacidos seleccionada del grupo que consiste en: epitopes de celulas T de clase II del MHC FLRVPSWKI (SEQ ID NO: 2) y FLRVPCWKI (SEQ ID NO: 1), o epitopes de celulas NKT FLRVPCW (SEQ ID NO: 63), y FLRVPSW (SEQ ID NO: 64), y en donde dicho motivo de oxidorreductasa y dicho epitope estan separados por una secuencia enlazadora de entre 3 a 7 aminoacidos que comprende la secuencia VRY. Los peptidos inmunogenicos derivados de la Glicoproteina de Mielina de Oligodendrocitos (MOG) para uso en el tratamiento de trastornos de desmielinizacion y la generacion de celulas T CD4+ citoliticas o celulas NKT contra celulas presentadoras de antigenos que presentan la secuencia del epitope MOG de tipo salvaje, para el tratamiento de esclerosis multiple.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20173201 | 2020-05-06 | ||
| PCT/EP2021/061985 WO2021148683A2 (en) | 2020-05-06 | 2021-05-06 | Peptides and methods for the treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240491A1 true PE20240491A1 (es) | 2024-03-15 |
Family
ID=70613608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002564A PE20240491A1 (es) | 2020-05-06 | 2021-05-06 | Peptidos y metodos para el tratamiento de esclerosis multiple |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230340061A1 (es) |
| EP (1) | EP4146676A2 (es) |
| JP (1) | JP2023525084A (es) |
| KR (1) | KR20230006905A (es) |
| CN (1) | CN115702162A (es) |
| AR (1) | AR122023A1 (es) |
| AU (1) | AU2021210629A1 (es) |
| CA (1) | CA3181368A1 (es) |
| CO (1) | CO2022017087A2 (es) |
| CU (1) | CU20220066A7 (es) |
| IL (1) | IL297945A (es) |
| MX (1) | MX2022013911A (es) |
| PE (1) | PE20240491A1 (es) |
| PH (1) | PH12022552979A1 (es) |
| TW (1) | TW202208413A (es) |
| WO (1) | WO2021148683A2 (es) |
| ZA (1) | ZA202212773B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2059256T3 (pl) | 2006-08-11 | 2017-02-28 | Life Sciences Research Partners Vzw | Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych |
| EP3915575A1 (en) * | 2020-05-29 | 2021-12-01 | Imnate Sarl | Vaccine formulations |
| WO2025105734A1 (ko) * | 2023-11-15 | 2025-05-22 | 주식회사 카인사이언스 | 탈수초 질환 치료용 펩타이드 및 이의 용도 |
| KR20260005781A (ko) * | 2024-07-02 | 2026-01-12 | 주식회사 카인사이언스 | 만성 염증성 탈수초 다발신경병증에 대한 펩타이드의 투여요법 |
| WO2026010306A1 (ko) * | 2024-07-02 | 2026-01-08 | 주식회사 카인사이언스 | 탈수초 질환 치료를 위한 펩타이드 및 ivig의 병용 요법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2059256T3 (pl) | 2006-08-11 | 2017-02-28 | Life Sciences Research Partners Vzw | Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych |
| ES2650236T3 (es) | 2008-02-14 | 2018-01-17 | Life Sciences Research Partners Vzw | Linfocitos T CD4+ con propiedades citolíticas |
| DE11787873T1 (de) * | 2010-11-25 | 2013-12-12 | Imnate Sarl | Immugene Peptide zur Verwendung bei der Vorbeugung und/oder Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Immunreaktionen auf Allofaktoren, allergischen Erkrankungen, Tumoren, Transplantatabstossungen und Immunreaktionen auf virale Vektoren |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| CY1120669T1 (el) * | 2012-08-03 | 2019-12-11 | Fwp Ip Aps | Συνδυαστικη θεραπεια για αγωγη σκληρυνσης κατα πλακας |
| CN105682648A (zh) * | 2013-08-26 | 2016-06-15 | 前进制药公司 | 用于以低的日剂量施用的含富马酸二甲酯的药物组合物 |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US11787849B2 (en) * | 2015-09-25 | 2023-10-17 | Imcyse Sa | Methods and compounds for eliminating immune responses to therapeutic agents |
| JP7320947B2 (ja) * | 2016-04-19 | 2023-08-04 | アンシス・エスア | 新規な免疫原性ＣＤ１ｄ結合ペプチド |
| US20200057048A1 (en) * | 2017-04-07 | 2020-02-20 | Uti Limited Partnership | Assay to measure the potency of receptor-ligand interactions in nanomedicines |
-
2021
- 2021-05-06 KR KR1020227042672A patent/KR20230006905A/ko not_active Withdrawn
- 2021-05-06 US US17/923,108 patent/US20230340061A1/en active Pending
- 2021-05-06 EP EP21721811.4A patent/EP4146676A2/en not_active Withdrawn
- 2021-05-06 AR ARP210101235A patent/AR122023A1/es not_active Application Discontinuation
- 2021-05-06 JP JP2022567648A patent/JP2023525084A/ja active Pending
- 2021-05-06 CU CU2022000066A patent/CU20220066A7/es unknown
- 2021-05-06 TW TW110116332A patent/TW202208413A/zh unknown
- 2021-05-06 AU AU2021210629A patent/AU2021210629A1/en not_active Abandoned
- 2021-05-06 CA CA3181368A patent/CA3181368A1/en active Pending
- 2021-05-06 CN CN202180043967.6A patent/CN115702162A/zh active Pending
- 2021-05-06 PH PH1/2022/552979A patent/PH12022552979A1/en unknown
- 2021-05-06 MX MX2022013911A patent/MX2022013911A/es unknown
- 2021-05-06 IL IL297945A patent/IL297945A/en unknown
- 2021-05-06 PE PE2022002564A patent/PE20240491A1/es unknown
- 2021-05-06 WO PCT/EP2021/061985 patent/WO2021148683A2/en not_active Ceased
-
2022
- 2022-11-23 ZA ZA2022/12773A patent/ZA202212773B/en unknown
- 2022-11-29 CO CONC2022/0017087A patent/CO2022017087A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021148683A3 (en) | 2021-09-23 |
| CU20220066A7 (es) | 2023-06-13 |
| IL297945A (en) | 2023-01-01 |
| AU2021210629A1 (en) | 2022-12-08 |
| JP2023525084A (ja) | 2023-06-14 |
| KR20230006905A (ko) | 2023-01-11 |
| CO2022017087A2 (es) | 2023-02-16 |
| EP4146676A2 (en) | 2023-03-15 |
| TW202208413A (zh) | 2022-03-01 |
| MX2022013911A (es) | 2022-11-30 |
| ZA202212773B (en) | 2024-04-24 |
| US20230340061A1 (en) | 2023-10-26 |
| WO2021148683A2 (en) | 2021-07-29 |
| PH12022552979A1 (en) | 2024-02-26 |
| AR122023A1 (es) | 2022-08-03 |
| CA3181368A1 (en) | 2021-07-29 |
| CN115702162A (zh) | 2023-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240491A1 (es) | Peptidos y metodos para el tratamiento de esclerosis multiple | |
| AR127118A2 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
| CY1125492T1 (el) | Πεγκυλιωμενα λιποσωματα για χορηγηση rna το οποιο κωδικοποιει ενα ανοσογονο | |
| MX2018012268A (es) | Receptores de celulas t. | |
| MX2010001086A (es) | Nueva inmunoterapia contra tumores neuronales y cerebrales. | |
| PE20180505A1 (es) | Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres | |
| CL2019003427A1 (es) | Nuevos péptidos (seq id n°180), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
| MX2018012265A (es) | Receptores de celulas t. | |
| CO2020015707A2 (es) | Casetes de expresión de α-glucosidasa de ácido optimizado con codón y métodos de uso del mismo | |
| PE20181490A1 (es) | Tratamientos contra el cancer de utero | |
| BRPI9912175A (pt) | peptídios de antígeno cd4-cdr2, composição farmacêutica compreendendo os mesmos bem como uso da mesma | |
| ES2138086T3 (es) | Constructo de peptido sintetico compuesto que provoca anticuerpos neutralizantes y linfocitos t citotoxicos contra hiv. | |
| PE20191529A1 (es) | Peptidos y metodos para el tratamiento de diabetes | |
| PE20180253A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer | |
| AR071510A1 (es) | Anticuerpos anti- factor d humanizados y sus usos | |
| PE20181897A1 (es) | Inmunoterapia contra el melanoma y otros tipos de cancer | |
| CL2023000426A1 (es) | Neoantígenos ras y usos de los mismos | |
| RU2009101191A (ru) | Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их | |
| RU2013131089A (ru) | Пептиды тем8 и содержащие их вакцины | |
| PE20211494A1 (es) | Peptidos inmunogenicos con motivos de oxidorreductasa mejorados | |
| MX2020012186A (es) | Presentacion de peptidos a celulas presentadoras de antigenos usando un vehiculo lipidico. | |
| MX2021012994A (es) | Administracion heterologa de vacunas tau. | |
| RU2009129531A (ru) | Вакцины на основе пептида foxp3 | |
| MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
| MX2022004598A (es) | Compuestos inmunogenicos para el tratamiento del cancer suprarrenal. |